Synlogic Inc (SYBX) Stock Analysis

Synlogic Inc (SYBX) is a publicly traded company in the HEALTHCARE sector. It trades at $0.69. This page summarizes the public market data, fundamentals, and frequently asked questions for SYBX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $0.69

Market Sentiment

Synlogic Inc currently has a Bearish sentiment score of -0.19.

About Synlogic Inc

Synlogic, Inc. is an innovative clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, dedicated to developing synthetic biotic drugs aimed at transforming the treatment landscape for cancer, inflammatory, and metabolic diseases. With a proprietary platform that harnesses the power of engineered probiotics, Synlogic's pipeline includes several novel therapeutic candidates designed to provide targeted treatment solutions with enhanced efficacy and safety profiles. ...

GNG Research Analysis

GNG Research scores Synlogic Inc (SYBX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for SYBX.

Frequently Asked Questions

Does SYBX pay dividends?

Synlogic Inc (SYBX) does not currently pay a regular dividend.